Nathan Stasko, PhD, is co-founder, President and Chief Executive Officer and a Director of Novan, Inc. Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through each of its private financings totaling more than $100 million, as well as the award of government grants and contracts totaling $15 million, the latter ultimately resulting in Novan’s national recognition as a Tibbetts Award winner for excellence in Small Business Innovation Research. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.
Brian Johnson is the Chief Commercial Officer responsible for Novan’s commercialization efforts including sales, marketing and managed care for the company’s dermatology products. Mr. Johnson brings to Novan nearly three decades of marketing and sales leadership at dermatology companies including Ortho Pharmaceutical Corporation (Johnson & Johnson’s Dermatological Division), Medicis Pharmaceutical Corporation and Galderma Laboratories, LLC where he served as Vice President of Prescription Marketing and Chief Digital Officer. At Galderma, he and his team quadrupled sales by launching category leaders like Epiduo®, Clobex® and Oracea®. In addition to Epiduo®, he participated in the sales and/or marketing of other leading acne brands including Retin-A®, Dynacin®, and Differin®.
Richard Peterson is the Chief Financial Officer responsible Novan’s financial operations, investor relations, and other corporate functions. Mr. Peterson has more than twenty years of successful financial leadership experience. Most recently, Mr. Peterson served as Executive Vice President, Chief Financial Officer and Treasurer of Medicis Pharmaceutical Corporation until its acquisition in 2012 by Valeant Pharmaceuticals International for $2.6 billion. During his time at Medicis, the company achieved tremendous growth in revenue and profitability with a suite of products including Solodyn®, one of the most successful selling acne products. Prior to joining Medicis, Mr. Peterson was a senior financial auditor with PricewaterhouseCoopers. He currently serves as a Director at Universal Insurance Holdings, Incorporated (NYSE: UVE).
M. Joyce Rico, MD, MBA, is the Chief Medical Officer who leads the company’s clinical development programs. Dr. Rico is a board-certified dermatologist who has served on the faculty at Duke University, New York University, Northwestern University and the University of Miami. As a physician, she provides the company with clinical leadership and strategic planning with 12 years of added industry experience in product development and medical affairs. At Fujisawa Astellas, Dr. Rico played a key role in the development, launch and post-marketing support for products treating acne, eczema, and psoriasis as well as anti-infectives. Dr. Rico also serves on the Board of Directors for the American Dermatologic Association and the Society for Investigative Dermatology.
Kevin Barber, MS, PhD, RAC, PMP is Vice President of Regulatory Affairs and leads the development and execution of Novan’s regulatory strategy. Dr. Barber has over 21 years of experience in pharmaceutical product development and biomedical research with a background in designing and implementing effective integrated regulatory plans. Most recently, Dr. Barber served as Vice President of Global Brand Regulatory Affairs at Actavis (formerly Watson Pharmaceuticals) where he was responsible for regulatory development of over 20 products and regulatory life cycle management of more than 150 approved products in US, Canadian, and European markets.
Stan Hollenbach, BS, JD, is the Vice President of Research and Nonclinical Development and leads the design and execution of all pharmacology and toxicology testing for the Company. Mr. Hollenbach has more than 25 years of experience in the biotechnology industry specializing in preclinical development of small molecules and proteins which includes participation in numerous US and European regulatory submissions. He worked previously at COR Therapeutics, Inc. with extensive experience in cardiovascular drug discovery. In 2003 COR was acquired by Millennium Pharmaceuticals, Inc. which became the cardiovascular franchise for the company. Most recently during his tenure at Portola Pharmaceuticals, Inc., he focused primarily on platelet and fibrin mediated thrombosis leading the preclinical development of orally bioavailable antiplatelet P2Y12 antagonists and factor Xa (fXa) inhibitors. Additionally, Mr. Hollenbach served in the US Army at the Letterman Army Institute of Research (LAIR) with research experience in emergency care and resuscitative therapy of combat casualties.
Jeff N. Hunter, MS, is the Vice President of Technical Operations and has been integral to the company’s execution and operational success since its inception. With more than 30 years of broad business experience including as co-founder and former CEO and Chairman of a small-cap public company, Mr. Hunter has built Novan’s corporate infrastructure systems as well as strengthened supply chain and business relationships. His versatility and in-depth understanding of the company’s business encompass manufacturing and product development. In 2013, the Triangle Business Journal recognized Mr. Hunter as a top executive in his field. In 2015, he was appointed to serve on the Board of Directors of the North Carolina Biotechnology Center.
Tim O’Sullivan, JD, MBA, is the Vice President of Intellectual Capital and spearheads the strategic development of the Company’s intellectual property portfolio. He manages Novan’s licensing strategy and is responsible for building the Company’s robust barriers to entry. Mr. O’Sullivan has more than 20 years of experience in developing intellectual property portfolios. Before joining Novan, Mr. O’Sullivan was the Director of Intellectual Property and Business Development for LED Lighting Solutions at Cree, Inc.